Home » Stocks » JAZZ

Jazz Pharmaceuticals PLC (JAZZ)

Stock Price: $167.71 USD 1.90 (1.15%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $168.00 +0.29 (0.17%) Jan 15, 7:32 PM
Market Cap 9.34B
Revenue (ttm) 2.28B
Net Income (ttm) 179.19M
Shares Out 55.55M
EPS (ttm) 3.16
PE Ratio 53.04
Forward PE 9.99
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $167.71
Previous Close $165.81
Change ($) 1.90
Change (%) 1.15%
Day's Open 166.09
Day's Range 165.00 - 168.12
Day's Volume 677,230
52-Week Range 87.74 - 168.12

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 4 days ago

Pharmaceutical stocks have many benefits, particularly when their products are in demand. And in 2021, that seems likely to be the case.

Other stocks mentioned: ABBV, BMY, ELAN, JNJ, MRNA, PFE
PRNewsWire - 1 week ago

DUBLIN, Jan. 4, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 39th Annual J.P. Morgan Healthcare ...

Zacks Investment Research - 3 weeks ago

Jazz (JAZZ) initiates the submission of a BLA to the FDA for the marketing approval of JZP-458 for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma.

Zacks Investment Research - 1 month ago

JAZZ announces the failure of a combination regimen of SCLC drug, Zepzelca, to meet primary endpoint in a late-stage study. However, overall study data seems promising for the drug.

PRNewsWire - 1 month ago

DUBLIN, Dec. 3, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ), along with its partner, PharmaMar (MSE: PHM), today announce results from the ATLANTIS Phase 3 multicenter, random...

Zacks Investment Research - 1 month ago

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 month ago

Is Jazz Pharmaceuticals (JAZZ) a great pick from the value investor's perspective right now? Read on to know more.

PRNewsWire - 2 months ago

DUBLIN, Nov. 17, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Jennifer Cook and Mark D. Smith, M.D. have been appointed to the Company's Board of Directors...

PRNewsWire - 2 months ago

DUBLIN, Nov. 10, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the following virtual healthcare confe...

Insider Monkey - 2 months ago

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our i...

PRNewsWire - 2 months ago

DUBLIN, Nov. 5, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 11 company-sponsored abstracts, in addition to two abstracts from collaboration trials with Th...

Schaeffers Research - 2 months ago

The shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) are up 5.9% at $156 at last check, after a third-quarter earnings and revenue beat.

Zacks Investment Research - 2 months ago

Jazz Pharmaceuticals (JAZZ) reports better-than-expected third-quarter 2020 earnings and revenues and ups its sales guidance for 2020.

Seeking Alpha - 2 months ago

Jazz Pharmaceuticals plc's (JAZZ) CEO Bruce Cozadd on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Jazz (JAZZ) delivered earnings and revenue surprises of 6.95% and 4.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 2 months ago

Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) moved higher by 7.9% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 5.12% year over ye...

PRNewsWire - 2 months ago

DUBLIN, Nov. 2, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2020 and updated its 2020 financial guidance. "We delive...

Benzinga - 2 months ago

Jazz Pharmaceuticals (NASDAQ: JAZZ) releases its next round of earnings this Monday, November 02. Here is Benzinga's essential guide to Jazz Pharmaceuticals's Q3 earnings report.

Zacks Investment Research - 2 months ago

Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

24/7 Wall Street - 2 months ago

It is almost hard to believe, in what has been one of the most unbelievable years in recent history, that Halloween is this weekend and Thanksgiving is right around the corner.

Other stocks mentioned: EXR, FCX, GOOGL, LLY, MDT, PH, RCL, WAT, WMT
Zacks Investment Research - 2 months ago

Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 2 months ago

DUBLIN and STAMFORD, Conn., Oct. 26, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) ("SpringWorks") today announced that Jazz Ph...

Other stocks mentioned: SWTX
PRNewsWire - 2 months ago

DUBLIN, Oct. 20, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the publication of the global Phase 3 double-blind, placebo-controlled, randomized-withdrawal, mul...

PRNewsWire - 2 months ago

DUBLIN, Oct. 19, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 third quarter financial results on Monday, November 2, 2020, after th...

The Motley Fool - 2 months ago

A second term for Trump would be music to the ears of these four companies.

Other stocks mentioned: ETSY, FB, XOM
Investopedia - 3 months ago

Nearby support on the charts suggests that the pharmaceuticals sector could be one to watch over the last few months of 2020.

Other stocks mentioned: XPH, ZTS
Seeking Alpha - 3 months ago

Jazz Pharmaceuticals: Long-Term Prospects Jazz Up A Modest Upside

Zacks Investment Research - 3 months ago

Jazz Pharmaceuticals (JAZZ) posts favorable top-line results from a phase III study on Xywav oral solution, which is being evaluated to treat adult patients with idiopathic hypersomnia. Shares...

Investors Business Daily - 3 months ago

Jazz Pharmaceuticals posted positive final-phase trials data for both effectiveness and safety for a drug therapy to treat a sleep disorder, sending JAZZ stock jumping back into a buy zone. Th...

PRNewsWire - 3 months ago

DUBLIN, Oct. 8, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line results from the Phase 3 double-blind, multicenter, placebo-controlled, randomize...

The Motley Fool - 3 months ago

Drug developers don't get much cheaper than this.

Other stocks mentioned: ALXN, EXEL
Zacks Investment Research - 3 months ago

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Other stocks mentioned: ZTS
The Motley Fool - 3 months ago

In case of a flash sale, scoop up shares of companies that are bound to bounce back.

Other stocks mentioned: ONEM, PTON
Investors Business Daily - 3 months ago

A Relative Strength Rating upgrade for Jazz Pharmaceuticals shows improving technical performance. The post Stock Upgrades: Jazz Pharmaceuticals Shows Rising Relative Strength appeared first o...

The Motley Fool - 3 months ago

Despite a poor performance of late, this biotech stock could bounce back.

PRNewsWire - 4 months ago

DUBLIN, Sept. 17, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the launch of Find the Right Fit (FindTheRightFit-sAML.com), a U.S.

PRNewsWire - 4 months ago

DUBLIN, Sept. 15, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its support of the American Heart Association's sleep health educational content aimed at improvi...

Business Wire - 4 months ago

SAN FRANCISCO--(BUSINESS WIRE)--Cleave Therapeutics Announces Research Collaboration with Jazz Pharmaceuticals in Acute Myeloid Leukemia (AML)

PRNewsWire - 4 months ago

DUBLIN, Sept. 9, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has signed a new research collaboration agreement with Redx Pharma plc (AIM: REDX...

PRNewsWire - 4 months ago

DUBLIN, Sept. 8, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at the following virtual investor confer...

Zacks Investment Research - 4 months ago

Earnings yield is a useful ratio for investors who have exposure to both stocks and bonds.

Other stocks mentioned: AN, GM, TOL, VSTO
Zacks Investment Research - 4 months ago

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

The Motley Fool - 4 months ago

These shell companies allow the businesses they acquire to go public much more quickly than an IPO would. Is it time to buy in?

Other stocks mentioned: INVA, TBPH, TXAC, TXG
Zacks Investment Research - 4 months ago

Jazz (JAZZ) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Investment Research - 4 months ago

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Other stocks mentioned: ZTS
PRNewsWire - 4 months ago

DUBLIN, Aug. 27, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 10 abstracts will be presented at Virtual SLEEP 2020, the 34th annual meeting of the Associat...

Zacks Investment Research - 5 months ago

Jazz Pharmaceuticals (JAZZ) reports better-than-expected second-quarter 2020 earnings and revenues. It raises its guidance for 2020.

The Motley Fool - 5 months ago

The drugmaker delivered solid growth in Q2 and upped its full-year outlook.

Seeking Alpha - 5 months ago

Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Jazz (JAZZ) delivered earnings and revenue surprises of 9.76% and 11.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

About JAZZ

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adu... [Read more...]

Industry
Biotechnology
IPO Date
Jun 1, 2007
CEO
Bruce C. Cozadd
Employees
1,620
Stock Exchange
NASDAQ
Ticker Symbol
JAZZ
Full Company Profile

Financial Performance

In 2019, JAZZ's revenue was $2.16 billion, an increase of 14.32% compared to the previous year's $1.89 billion. Earnings were $523.37 million, an increase of 17.06%.

Financial Statements

Analyst Forecasts

According to 20 analysts, the average rating for JAZZ stock is "Buy." The 12-month stock price forecast is 181.74, which is an increase of 8.37% from the latest price.

Price Target
$181.74
(8.37% upside)
Analyst Consensus: Buy